卡格列净在KDIGO风险分层中的心血管和肾脏结局相对与绝对风险降低:CANVAS项目分析
该研究为CANVAS项目的事后分析,纳入10,142例2型糖尿病高危患者,按KDIGO风险分类评估卡格列净对心血管和肾脏结局的相对与绝对效应。结果显示,卡格列净的相对效应在各KDIGO风险类别中一致,但绝对风险降低在高KDIGO风险类别中更大。
要点
- 卡格列净相对效应在各KDIGO风险类别中一致。
- 绝对风险降低在高KDIGO风险类别中更大。
- KDIGO分类或可识别更受益于卡格列净的个体。
核心结论
- 卡格列净的相对效应在各KDIGO风险类别中相似,但绝对风险降低在高KDIGO风险个体中可能更大。
研究设计与样本
- CANVAS项目的事后分析,随机分配10,142例2型糖尿病高危且eGFR≥30mL/min/1.73m2的患者接受卡格列净或安慰剂。
主要发现
- 在10,031例(98.9%)有基线eGFR和UACR数据的患者中,KDIGO低、中、高、极高风险类别比例分别为58.6%、25.8%、10.6%、5.0%。
- 卡格列净对主要结局(HR 0.86;95% CI 0.75-0.97)的相对效应在各KDIGO风险类别中一致(P趋势=0.2),其他心血管和肾脏结局结果相似。
- 主要结局的绝对降低在高KDIGO风险类别中更大(P趋势=0.03),心血管死亡或心衰住院复合结局(P趋势=0.06)和慢性eGFR斜率(P趋势=0.04)呈现类似模式。
关键数值与推荐
- 主要结局为心血管死亡、非致死性心肌梗死或非致死性卒中的复合终点。
- KDIGO风险分类基于eGFR和尿白蛋白-肌酐比值。
临床怎么用
- 对于高KDIGO风险的2型糖尿病患者,卡格列净可能带来更大的绝对终点器官保护获益,可优先考虑使用。
局限性
- 主要为低肾脏风险人群,高KDIGO风险类别参与者相对较少,且排除了eGFR<30mL/min/1.73m2的个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Canagliflozin reduces the risk for cardiovascular and kidney outcomes in type 2 diabetes. This study aimed to assess the relative and absolute effects of canagliflozin on clinical outcomes across different KDIGO (Kidney Disease: Improving Global Outcomes) risk categories based on estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio. STUDY DESIGN: Post hoc analysis of the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. SETTINGS & PARTICIPANTS: The CANVAS Program randomly assigned 10,142 participants with type 2 diabetes at high cardiovascular risk and with eGFR≥30mL/min/1.73m2 to treatment with canagliflozin or placebo. INTERVENTION(S): Canagliflozin or matching placebo. OUTCOMES: The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, with a set of other cardiovascular and kidney prespecified outcomes. RESULTS: Of 10,142 participants, 10,031 (98.9%) had available baseline eGFR and urinary albumin-creatinine ratio data. The proportion of participants in low-, moderate-, high-, and very high-risk KDIGO categories was 58.6%, 25.8%, 10.6%, and 5.0%, respectively. The relative effect of canagliflozin on the primary outcome (HR, 0.86; 95% CI, 0.75-0.97) was consistent across KDIGO risk categories (P trend=0.2), with similar results for other cardiovascular and kidney outcomes. Absolute reductions in the primary outcome were greater within higher KDIGO risk categories (P trend=0.03) with a similar pattern of effect for the composite of cardiovascular death or hospitalization for heart failure (P trend=0.06) and for chronic eGFR slope (P trend = 0.04). LIMITATIONS: Predominantly a low kidney risk population, relatively few participants in higher KDIGO risk categories, and exclusion of individuals with eGFR<30mL/min/1.73m2. CONCLUSIONS: Although the relative effects of canagliflozin are similar across KDIGO risk categories, absolute risk reductions are likely greater for individuals at higher KDIGO risk. The KDIGO classification system may be able to identify individuals who might derive greater benefits for end-organ protection from treatment with canagliflozin. FUNDING: This post hoc analysis was not specifically funded. The original CANVAS Program trials were funded by Janssen Research & Development, LLC and were conducted as a collaboration between the funder, an academic steering committee, and an academic research organization, George Clinical. TRIAL REGISTRATION: The original trials of the CANVAS Program were registered at ClinicalTrials.gov with study numbers NCT01032629 and NCT01989754.
引用
- Neuen BL, Ohkuma T, Neal B, et al. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. Am J Kidney Dis. 2020. PMID: 32971190. doi:10.1053/j.ajkd.2020.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。